Ifosfamide Baxter Healthcare

Ifosfamide, the active ingredient in Ifosfamide Baxter Healthcare, is a alkylating agent (nitrogen mustard) presented as an injectable solution for intravenous use. It treats a range of solid tumours and haematologic malignancies in adult and paediatric patients.

GNH USA supplies Ifosfamide Baxter Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ifosfamide is employed in oncology as a DNA‑alkylating agent for several tumour types. - Testicular cancer: used in combination regimens to achieve tumour shrinkage and improve survival. - Soft tissue sarcoma: incorporated into multi‑drug protocols to control disease progression. - Ovarian cancer: administered as part of salvage chemotherapy for resistant disease. - Lymphoma: utilized in refractory cases to induce remission. - Wilms tumor: given in pediatric protocols to enhance cure rates. - Neuroblastoma: applied in high‑risk treatment schedules to reduce tumour burden.

Ifosfamide may cause a range of adverse reactions, which are monitored during therapy.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during treatment. - Myelosuppression: reduced white blood cells, red cells and platelets. - Fatigue: generalized tiredness often reported by patients. - Alopecia: temporary hair loss during cycles.

Serious or Rare Side Effects: - Hemorrhagic cystitis: bladder irritation that may cause bleeding. - Neurotoxicity: confusion, seizures or encephalopathy in severe cases. - Nephrotoxicity: impaired kidney function requiring monitoring.

When using Ifosfamide, clinicians should observe several safety measures. - Hydration: ensure adequate intravenous fluids to reduce risk of bladder toxicity. - Mesna co‑administration: provide uroprotective agent to prevent hemorrhagic cystitis. - Renal function monitoring: assess serum creatinine and electrolytes before each dose. - Neurological assessment: watch for signs of encephalopathy or seizures. - Pregnancy category D: avoid use in pregnant women unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Ifosfamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase toxic metabolite levels. - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heighten risk of kidney injury.

Moderate Interactions (Monitor Closely): - CYP inducers (e.g., rifampin, phenytoin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk. - Other myelosuppressive drugs: increase likelihood of severe bone‑marrow suppression.